利用人工智能获得Molecule.ai以刺激癌症药物的研发。 Shuttle Pharma to acquire Molecule.ai to boost cancer drug development with AI.

Shuttle Pharma 已签署收购 Molecule.ai 的最终意向书，旨在利用后者的人工智能驱动的药物发现平台来增强其肿瘤学产品线。 Shuttle Pharma has signed a definitive letter of intent to acquire Molecule.ai, aiming to leverage the latter's AI-driven drug discovery platform to enhance its oncology pipeline. 通过整合先进的分子分析,移动定位辐射治疗作为一种更具针对性的治疗。 The move positions radiation therapy as a more targeted treatment by integrating advanced molecular analysis. 这项交易,在最后尽职调查之前,可以加快精确癌症疗法的开发。 The deal, pending final due diligence, could accelerate development of precision cancer therapies.